Literature DB >> 15288763

Rapid signalling pathway activation by androgens in epithelial and stromal cells.

Gabriella Castoria1, Maria Lombardi, Maria Vittoria Barone, Antonio Bilancio, Marina Di Domenico, Antonietta De Falco, Lilian Varricchio, Daniela Bottero, Merlin Nanayakkara, Antimo Migliaccio, Ferdinando Auricchio.   

Abstract

Estradiol rapidly activates Src as well as the Src-dependent pathway in human mammary cancer-derived MCF-7 cells, in human prostate cancer-derived LNCaP cells and in Cos cells transiently expressing hERs [EMBO J. 15 (1996) 1292; EMBO J. 17 (1998) 2008]. In addition, estradiol immediately stimulates, yes, an ubiquitous member of the Src kinase family, in human colon carcinoma-derived Caco-2 cells [Cancer Res. 56 (1996) 4516]. Progestins and androgens activate the same pathway in human mammary and prostate cancer-derived cells [EMBO J. 17 (1998) 2008; EMBO J. 19 (2000) 5406]. We observed that estradiol also stimulates the phosphatidylinositol-3-kinase (PI3K)/AKT pathway in MCF-7 cells [EMBO J. 20 (2001) 6050]. In these cells, activation of the Src- and the PI3 K-dependent pathways is simultaneous and mediated by direct interactions of the two kinases with ERalpha. The signalling pathway activation by sex-steroid hormones leads to DNA synthesis and cell growth in human mammary and prostate cancer-derived cells [EMBO J. 19 (2000) 5406; EMBO J. 20 (2001) 6050; EMBO J. 18 (1999) 2500]. Furthermore, androgen stimulation of NIH3T3 fibroblasts activates the same pathways triggered by this hormone in LNCaP cells and promotes the S-phase entry or cytoskeleton changes in these cells [J. Cell Biol. 161 (2003) 547]. All the described effects are rapid and require classic steroid receptors, but, surprisingly, not their transcriptional activity. Indeed, a transcriptionally inactive mutant of hER mediates the estrogen-stimulated DNA synthesis of NIH3T3 fibroblasts [EMBO J. 18 (1999) 2500]. Furthermore, AR in NIH3T3 cells does not enter nuclei and is unable to respond to the hormone with transcription stimulation, whereas it activates signaling pathways and triggers important biological responses. Signaling pathway activation by steroids has also been described by other groups under different experimental conditions and/or in different cell types. In these cells, steroid stimulation triggers various effects, such as neuroprotection, vasorelaxation or bone protection [J. Neurosci. Res. 60 (2000) 321; Nature 407 (2000) 538; J. Cell Biochem. 76 (1999) 206]. Analysis of the mechanisms responsible for the hormone-dependent and steroid receptor-mediated pathway activation in epithelial as well as stromal cells reveals immediate association of steroid receptors with extranuclear signaling effectors [EMBO J. 17 (1998) 2008; Cancer Res. 56 (1996) 4516; EMBO J. 19 (2000) 5406; EMBO J. 20 (2001) 6050; J. Cell Biol. 161 (2003) 547]. These results further highlight the central role of the hormone-regulated protein-protein interactions in the steroid action. They also offer the possibility of interfering with important activities of hormones, such as proliferation or survival, cytoskeleton changes as well as invasiveness and vasorelaxation, without affecting the steroid effects that depend on receptor transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288763     DOI: 10.1016/j.steroids.2004.05.001

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  18 in total

Review 1.  Motoneuron injury and repair: New perspectives on gonadal steroids as neurotherapeutics.

Authors:  Julie E Tetzlaff; Christopher B Huppenbauer; Lisa Tanzer; Thomas D Alexander; Kathryn J Jones
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 3.  Multiple pathways transmit neuroprotective effects of gonadal steroids.

Authors:  Damani N Bryant; Laird C Sheldahl; Lisa K Marriott; Robert A Shapiro; Daniel M Dorsa
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 4.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.

Authors:  Xin Yuan; Tong Li; Hongyun Wang; Tao Zhang; Moumita Barua; Robert A Borgesi; Glenn J Bubley; Michael L Lu; Steven P Balk
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

6.  Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.

Authors:  Takashi Kobayashi; Takahiro Inoue; Yosuke Shimizu; Naoki Terada; Atsushi Maeno; Yoichiro Kajita; Toshinari Yamasaki; Tomomi Kamba; Yoshinobu Toda; Yoshiki Mikami; Tomomi Yamada; Toshiyuki Kamoto; Osamu Ogawa; Eijiro Nakamura
Journal:  Mol Endocrinol       Date:  2010-03-04

Review 7.  Androgen action and metabolism in prostate cancer.

Authors:  Sean M Green; Elahe A Mostaghel; Peter S Nelson
Journal:  Mol Cell Endocrinol       Date:  2012-03-20       Impact factor: 4.102

Review 8.  Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs.

Authors:  C N Kent; I K Guttilla Reed
Journal:  Clin Transl Oncol       Date:  2016-02-08       Impact factor: 3.405

9.  G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.

Authors:  Jianjun Liu; Hyewon Youn; Jun Yang; Ningchao Du; Jihong Liu; Hongwei Liu; Benyi Li
Journal:  Prostate       Date:  2011-02-09       Impact factor: 4.104

Review 10.  Classical androgen receptors in non-classical sites in the brain.

Authors:  Sara Sarkey; Iñigo Azcoitia; Luis Miguel Garcia-Segura; Daniel Garcia-Ovejero; Lydia L DonCarlos
Journal:  Horm Behav       Date:  2008-03-06       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.